healthy1

There seems to be a slew of ongoing trial studies available for possible, new MS medications. Up until now, I had not seen too many promising oral medications. Although I have chosen not to take any meds for my CIS/MS (mainly in part because they are only injectables currently available), this piqued my interest nonetheless:

“Oral Drug Study Shows Promising Results”

Results of a clinical trial of oral BG00012 show that the highest-tested doses led to a 69% reduction in active inflammation on MRI scans. Further clinical and safety data from the Phase 3 studies will help determine if this oral therapy can be used effectively and safely in people with MS.

For the Phase 2 study, 257 people with relapsing-remitting MS were assigned to receive a low, medium or high dose of daily oral BG0012, or inactive placebo, for 24 weeks. Although its exact mechanism of action is not known, BG00012, an oral fumarate, is thought to inhibit immune cells and molecules and could be protective against damage to the central nervous system.

Adverse reactions included abdominal pain, flushing, headache, fatigue and feeling hot. Oh well. Not too bad…but back to the drawing board I say. Who wants side effects on top of dealing with a disease?

Trackback URI | Comments RSS